Locanabio to Participate in Upcoming Investor Conferences

SAN DIEGO, Nov. 22, 2021 /PRNewswire/ -- Locanabio, Inc., a genetic medicines company developing therapeutics for patients with severe neuromuscular, neurodegenerative and retinal diseases, today announced that its leadership team will participate in the following upcoming investor conferences:

Piper Sandler 33^rd Annual Healthcare Conference, November 29-December 2, 2021

• Jim Burns, Ph.D., chief executive officer at Locanabio, will present a company overview including recent preclinical and business achievements. The presentation will be pre-recorded and available for registered attendees to watch at their convenience during the conference. The presentation will also be available on the Piper Sandler Healthcare Conference website at https://pipersandler.zoom.us/rec/play/UmCM738_rjjt3hRnSA2xZIEL1tc0hMwR2TzSMKt9rWYetkjbYUAsc6kMhkEjaOPI_SMe39ZmgqJga59U.XC_WyuQ55zwO_lhJ starting on November 22, 2021 and will be available for 90 days following the presentation.

Evercore ISI 4^th Annual HealthCONx Conference, November 30-December 2, 2021

• Dr. Burns will participate in a fireside chat on Thursday, December 2, 2021 at 8:25 a.m. ET. A live webcast will be available on the Events & Presentations section of the company's website at https://locanabio.com/news/#events. The webcast will be available for 90 days following the fireside chat.

About Locanabio, Inc.
Locanabio is a leader in developing a new class of genetic medicines that has the potential to significantly improve the lives of patients with devastating genetic diseases by correcting the message of disease-causing RNA. Our proprietary platform, CORRECTx™, uses gene therapy to deliver RNA-binding protein systems that can be engineered to selectively manipulate disease-causing RNA by multiple mechanisms. Our systems are designed to provide a durable therapy with a single administration without altering a cell's DNA. Locanabio's CORRECTx platform has applications across a range of tissues and diseases and we are currently advancing programs in neurodegenerative, neuromuscular and retinal diseases. For more information, visit www.locanabio.com.

Media Contact
Jenna Urban
Berry & Company
[email protected] 
+1-212-253-8881

SOURCE Locanabio, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED